寡转移性前列腺癌中转移灶导向治疗与观察的长期结局及疗效遗传预测因素:STOMP与ORIOLE试验分析
该分析汇总STOMP与ORIOLE两项随机试验,比较转移灶导向治疗(MDT)与观察在寡转移性去势敏感性前列腺癌(omCSPC)中的长期结局。中位随访52.5个月,MDT较观察延长中位无进展生存期(汇总HR 0.44,95%CI 0.29-0.66,P<.001),高风险突变特征可能有助于MDT后风险分层。
要点
- 中位随访52.5个月,MDT较观察延长中位PFS(汇总HR 0.44,95%CI 0.29-0.66,P<.001)。
- MDT获益在高风险突变患者中最大(HR 0.05 vs 无高风险突变HR 0.42,交互P=.12)。
- MDT队列中无高风险突变者中位PFS 13.4个月,有高风险突变者7.5个月(HR 0.53,95%CI 0.25-1.11,P=.09)。
核心结论
- omCSPC中仅有的两项随机试验的长期结局提示,MDT较观察具有持续临床获益。
- 高风险突变特征可能有助于MDT后治疗结局的风险分层。
研究设计与样本
- 汇总STOMP与ORIOLE两项随机试验,分析omCSPC患者MDT与观察的长期结局并评估高风险突变特征的风险分层能力。
- 主要终点为采用Kaplan-Meier法计算的无进展生存期(PFS)。
- 高风险突变定义为ATM、BRCA1/2、Rb1或TP53内的致病性体细胞突变。
主要发现
- 全组中位随访52.5个月。
- MDT较观察延长中位PFS(汇总HR 0.44,95%CI 0.29-0.66,P<.001)。
- MDT获益在高风险突变患者中最大(高风险突变HR 0.05,无高风险突变HR 0.42,交互作用P=.12)。
- MDT队列中,无高风险突变者中位PFS为13.4个月,有高风险突变者为7.5个月(HR 0.53,95%CI 0.25-1.11,P=.09)。
关键数值与推荐
- 高风险突变定义为ATM、BRCA1/2、Rb1或TP53内的致病性体细胞突变。
- 中位PFS:MDT较观察延长,汇总HR 0.44(95%CI 0.29-0.66,P<.001)。
- MDT队列中位PFS:无高风险突变13.4个月 vs 有高风险突变7.5个月(HR 0.53,95%CI 0.25-1.11,P=.09)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.
引用
- Deek MP, Van der Eecken K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022. PMID: 36001857. doi:10.1200/JCO.22.00644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。